Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28100280 | 0.79 | POLB (0.39) | CES1MAPTCYP3A4TDP1MEN1 | |
| SCHEMBL229639 | 0.74 | LMNA (0.58) | CES1MAPTTDP1KMT2AMAPK1 | |
| SCHEMBL1542178 | 0.73 | F2 (0.39) | CES1MAPTCYP3A4TDP1MEN1 | |
| SCHEMBL18831925 | 0.73 | TSHR (0.46) | CES1MAPTCYP3A4TDP1KMT2A | |
| SCHEMBL489956 | 0.72 | MAPT (0.44) | CES1MAPTCYP3A4TDP1MEN1 | |
| SCHEMBL5592713 | 0.71 | CES2 (0.54) | CES1MAPTF2LMNAALDH1A1 | |
| SCHEMBL28648121 | 0.70 | ALDH1A1 (0.42) | CES1MAPTCYP3A4TDP1MEN1 | |
| SCHEMBL28786233 | 0.69 | MAPT (0.41) | CES1MAPTCYP3A4TDP1MEN1 | |
| SCHEMBL812710 | 0.69 | TSHR (0.52) | CES1MAPTCYP3A4TDP1MEN1 | |
| SCHEMBL302163 | 0.69 | ALDH1A1 (0.43) | CES1MAPTCYP3A4TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4650868-A | 7-deazapurine derivatives useful as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-17 | — | — | US | claimed |
| US-6696500-B2 | BIOACTIVE SUBSTANCE HAVING ACIDIC GROUP AND A BIODEGRADABLE POLYMER HAVING AN OPTIONALLY PROTECTED BASIC GROUP, SUCH AS A POLYLACTONE THAT HAS BEEN ESTERIFIED, AMIDATED, OR THIOESTERIFIED WITH A COMPOUND HAVING CYCLIC AMINO GROUPS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| EP-0815853-B1 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20010038854-A1 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6264970-B1 | BIODEGRADABLE POLYMER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-0815853-A2 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-4650868-A | 7-deazapurine derivatives useful as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-17 | — | — | US | disclosed |
| EP-0160910-A2 | 7-Deazapurine derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1985-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010038854-A1 | Sustained-release preparation | BMP2, PGF, AREG | CES1 2072/4885MAPT 4028/4885CYP3A4 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.